Page last updated: 2024-12-08
3,6-dichlorocarbazole
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3,6-dichlorocarbazole: from Bavarian soil; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 236487 |
CHEMBL ID | 5090876 |
SCHEMBL ID | 607827 |
MeSH ID | M0558220 |
Synonyms (28)
Synonym |
---|
9h-carbazole,6-dichloro- |
carbazole,6-dichloro- |
3,6-dichlorocarbazole |
5599-71-3 |
nsc-39031 |
nsc39031 |
MAYBRIDGE1_002023 |
D3751 |
HMS547D21 |
3,6-dichloro-9h-carbazole |
A830886 |
AKOS003618109 |
FT-0614754 |
SCHEMBL607827 |
cyto2d4 |
3,6-dichloro-9h-carbazole # |
9h-carbazole, 3,6-dichloro- |
carbazole, 3,6-dichloro- |
mfcd00218271 |
DTXSID40284786 |
AS-58458 |
AMY18345 |
A12642 |
CS-0115943 |
CHEMBL5090876 |
doi:10.14272/bimdtnqpzwjkpl-uhfffaoysa-n.1 |
10.14272/BIMDTNQPZWJKPL-UHFFFAOYSA-N.1 |
SY051103 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (9)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1827209 | Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as oxacillin MIC at 10 uM after 18 hrs by CLSI protocol based broth microdilution assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA. |
AID1827148 | Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as fold change in oxacillin MIC at 10 uM after 18 hrs by CLSI protocol based broth microdilution assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA. |
AID1827237 | Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus USA100 assessed as oxacillin MIC at 10 uM after 18 hrs by CLSI protocol based broth microdilution assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA. |
AID1827138 | Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of bacterial growth after 18 hrs by CLSI protocol based broth microdilution assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA. |
AID1827234 | Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus USA100 assessed as fold change in oxacillin MIC at 10 uM after 18 hrs by CLSI protocol based broth microdilution assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA. |
AID1827211 | Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus COL assessed as oxacillin MIC at 10 uM after 18 hrs by CLSI protocol based broth microdilution assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA. |
AID1827216 | Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 assessed as fold change in oxacillin MIC at 10 uM after 18 hrs by CLSI protocol based broth microdilution assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA. |
AID1827226 | Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus COL assessed as fold change in oxacillin MIC at 10 uM after 18 hrs by CLSI protocol based broth microdilution assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA. |
AID1827230 | Potentiation of oxacillin induced antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 assessed as oxacillin MIC at 10 uM after 18 hrs by CLSI protocol based broth microdilution assay | 2022 | ACS medicinal chemistry letters, Mar-10, Volume: 13, Issue:3 | Identification and Evaluation of Brominated Carbazoles as a Novel Antibiotic Adjuvant Scaffold in MRSA. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (60.00) | 24.3611 |
2020's | 4 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (10.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (90.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |